Emerald
Emerald Innovations builds a touchless radio-wave sensor and machine learning platform that passively monitors in-home health metrics for pharmaceutical clinical trials, serving large pharma companies running Phase 2 and Phase 4 studies across neurology, immunology, and rare diseases.
- Company typePrivate
- Founded2016
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Emerald does
Emerald Innovations is a Cambridge, Massachusetts-based health technology company that has commercialized a touchless radio-wave sensor paired with proprietary machine learning algorithms to passively monitor human movement, vital signs, gait, sleep, and behavior in the home without requiring wearables, charging, or patient interaction. The platform comprises a hardware sensor ("Emerald"), a cloud infrastructure ("Emerald Cloud") that ingests encrypted wireless signal data, and proprietary ML pipelines that extract clinical-grade endpoints including gait velocity, breathing patterns, sleep stages, and 3D through-wall pose estimation. Published, peer-reviewed research in Science Translational Medicine and Nature Medicine reports an AUC of 0.90 for Parkinson's disease detection on held-out data and 0.85 on external test sets, with severity estimation correlating with the MDS-UPDRS clinical scale at R=0.94 across a dataset of 7,671 individuals.
The company's commercial model targets large pharmaceutical companies and research consortia running Phase 2 and Phase 4 clinical trials in neurology, immunology, and rare diseases, delivering a turnkey solution of hardware deployment, in-home monitoring, and analytics delivery to sponsors. Revenue is generated through subscription-based clinical trial monitoring services bundled with hardware kits, sold via direct enterprise field sales with quote-based pricing. Named customers and partners include Aspen Neuroscience, Verge Genomics, BlueRock Therapeutics, the Rett Syndrome Research Trust, and Rune Labs, with the company claiming repeat contracts among the world's largest pharmaceutical companies. Emerald is bootstrapped, cashflow positive, and 100% employee owned, with roughly 11-50 employees and a leadership team anchored by MIT faculty and 50+ MIT-affiliated engineers and scientists working from the Cambridge Innovation Center in Kendall Square.
The company's strategic posture combines deep academic IP (patented ML and signal processing), peer-reviewed clinical validation, and selective pharma partnerships, while a recent partnership with Switzerland-based DIC signals intent to extend the underlying sensor technology into adjacent "physical AI" applications beyond clinical trials.
Emerald firmographics
Firmographics- Name
- Emerald
- Legal name
- Emerald Innovations
- Website
- https://emeraldinno.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Emerald Innovations builds a touchless radio-wave sensor and machine learning platform that passively monitors in-home health metrics for pharmaceutical clinical trials, serving large pharma companies running Phase 2 and Phase 4 studies across neurology, immunology, and rare diseases.
- Ownership category
- akta.pro rank
Emerald industry classification
Industry- Product category
- Digital Health Monitoring for Clinical Trials
- akta.pro primary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
- akta.pro secondary industries
- Wearables & Consumer IoT Integration Platforms (BYOD) (HLACAFAF), Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension) (HLACAPAD), Federated Learning & On-Device Personalization (HDAAAJAG), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)
Keywords
Where Emerald is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Emerald business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Monitoring Services: Emerald provides continuous clinical data collection services for drug development to pharmaceutical companies in Phase 2 and Phase 4 clinical trials. The company handles setup, installation, operation and data collection.
- Hardware Device Sales: Emerald devices (hardware kits) are delivered to participants with everything included for installation. Hardware is provided as part of the monitoring service.
- Health Analytics Delivery: At completion of studies, health analytics are delivered to sponsors via secure mechanisms.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
Emerald product offering
Product offeringCore offering
Emerald provides a touchless wireless sensor device combined with a cloud-based machine learning platform that passively monitors radio waves in the home to detect human movements and extract health metrics (gait, mobility, respiration, sleep stages, pose) without wearables, charging, or patient interaction. Data is transmitted over encrypted connections to the cloud where proprietary ML algorithms produce clinical endpoints used by pharmaceutical and biotech sponsors in Phase 2 and Phase 4 clinical trials across neurology, immunology, and rare diseases.
Product overview
Emerald Innovations offers a unified health analytics platform consisting of a hardware sensor device (Emerald) paired with a cloud-based machine learning platform (Emerald Cloud). The Emerald device is a touchless wireless sensor that passively monitors radio waves in the home to detect human movements and extract health metrics without requiring any patient interaction. Data is transmitted over encrypted connections to the Emerald Cloud, where proprietary machine learning algorithms process the signals to extract clinical endpoints including gait velocity, sleep stages, breathing patterns, and pose estimation. The platform is primarily used by pharmaceutical companies for Phase 2 and Phase 4 clinical trials across neurology, immunology, and rare diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Emerald (touchless wireless sensor device) A touchless wireless sensor device that monitors radio waves in the home to detect movements of people and extract health metrics (gait, respiration, sleep, pose) without requiring wear, charging, or manual data synchronization. Sold primarily to pharmaceutical and biotech sponsors as part of clinical trial deployments.
- Emerald Cloud Cloud infrastructure that securely receives and stores encrypted data from Emerald devices and applies proprietary machine learning algorithms to extract clinical health metrics for clinical trial participants.
- Emerald Platform A distributed end-to-end platform combining reliable, high-performance IoT sensors that collect and process wireless signals with cloud infrastructure that runs AI/ML to produce accurate, detailed health analytics for clinical trials and remote health monitoring.
Quantifiable outcome
- AI model detects Parkinson's disease with AUC of 0.90 and 0.85 on held-out and external test sets
- +2 more outcomes
Companies that use Emerald
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles1 record
Emerald technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Emerald partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- DICcoreDIC has entered into a partnership with Switzerland-based Emerald to accelerate business development in the physical AI domain. This partnership aims to create new business opportunities using Emerald's sensor technology.
- Aspen NeurosciencecorePartnership to incorporate both active and passive digital health monitoring in trial-ready cohort screening study for Parkinson's disease. Emerald provides passive monitoring to capture motor symptom activity over time.
- Verge GenomicscorePartnership to incorporate Emerald's digital health technology into ALS Phase 1b proof-of-concept clinical trial. Emerald enables collection of dense amounts of unbiased, objective patient function data.
- BlueRock TherapeuticscorePartnership to incorporate wearable and invisible contactless digital health technologies in Parkinson's disease clinical trial. Emerald collects unbiased, objective and continuous measure of disease progression.
- Rune LabscoreJoint partnership with Rune Labs to incorporate both active and passive digital health monitoring in Parkinson's disease screening studies.
- Rett Syndrome Research Trust (RSRT)coreRSRT awards partnership with Emerald to continue biomarker work, guided by Biomarker Consortium and FDA advice. Emerald provides direct, objective measures of symptoms captured continuously over days, weeks, months or longer.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Emerald competitors and assessment
Company assessmentDirect peers
- Biofourmis: Boston-based AI health company providing remote monitoring and digital biomarker platforms for clinical trials and care management. Directly comparable as a pharma-focused RPM platform using continuous patient data collection in clinical trial settings.
- ActiGraph: Leading provider of wearable activity and sleep monitors used as digital endpoints in clinical trials across pharma, academic, and government research. Comparable as a clinical trial digital biomarker vendor serving overlapping neurology and rare disease sponsors.
- VivoSense: Specialized in wearable biosensor digital endpoints for clinical trials, with deep roots in regulatory-grade sensor analytics. Highly comparable to Emerald in serving pharma with continuous patient-generated health data.
- Empatica: Maker of FDA-cleared wearable biosensors (EpiMonitor) and digital biomarkers for neurology clinical trials, including epilepsy and Parkinson's. Closely comparable in disease focus, clinical trial use case, and pharma customer base.
- Medable: Decentralized clinical trial platform connecting patients, sites, and sponsors with eCOA, ePRO, and remote data capture. Comparable as an enabling platform for at-home clinical trial data collection in pharma.
- Cambridge Cognition: Digital health company specializing in CNS clinical trial endpoints, including cognitive assessments and digital biomarkers for neuroscience drug development. Comparable for the neurology clinical trial use case.
Broad incumbents
- Clario: Formed by the merger of ERT and Bioclinica, Clario is one of the largest providers of clinical trial endpoint technology and eCOA solutions. Comparable as a broad incumbent serving the same pharma sponsors across trial modalities.
- Medidata (Dassault Systèmes): Industry-leading clinical trial technology platform (Rave, eCOA, Sensor Cloud) used by the majority of large pharma sponsors. Comparable as a broad incumbent in digital trial endpoints that has integrated third-party wearable/RPM data.
- IQVIA: Largest global CRO with deep digital health and decentralized trial capabilities, including its own RPM and digital biomarker offerings. Comparable as a broad incumbent serving pharma across the full clinical development lifecycle.
- iRhythm Technologies: Public digital health company with FDA-cleared wearable cardiac monitor (Zio) and AI-based arrhythmia detection platform. Comparable as a connected health monitoring company combining proprietary hardware, AI, and clinical evidence at scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Emerald social profiles
Digital presenceEmerald financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emerald leadership team
Management profileNumber of profiles
Profiles4 records
Emerald funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emerald M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emerald
What does Emerald do?
Emerald provides a touchless wireless sensor device combined with a cloud-based machine learning platform that passively monitors radio waves in the home to detect human movements and extract health metrics (gait, mobility, respiration, sleep stages, pose) without wearables, charging, or patient interaction. Data is transmitted over encrypted connections to the cloud where proprietary ML algorithms produce clinical endpoints used by pharmaceutical and biotech sponsors in Phase 2 and Phase 4 clinical trials across neurology, immunology, and rare diseases.
Is Emerald a public or private company?
Emerald is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Emerald founded?
Emerald was founded in 2016. It employs 11 to 50 people.
Where is Emerald based?
Emerald is headquartered in Cambridge, United States, in the North America region.
How does Emerald make money?
Three revenue lines are on record. Clinical Trial Monitoring Services are the primary driver. The others are hardware Device Sales and health Analytics Delivery.
Who are Emerald's main competitors?
Direct peers on record are Biofourmis, ActiGraph, VivoSense, Empatica, Medable and Cambridge Cognition. Broad incumbents are Clario, Medidata (Dassault Systèmes), IQVIA and iRhythm Technologies.
Does Emerald have an API?
No public API is recorded for Emerald.
What industry is Emerald in?
Emerald's product category is Digital Health Monitoring for Clinical Trials. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAFAF, Wearables & Consumer IoT Integration Platforms (BYOD).